Stryker revealed that it has completed the acquisition of Inari Medical, a company that offers solutions for venous thromboembolism (VTE) clot removal without using thrombolytic drugs.

The deal, which was announced last month, was valued at $80 per share. This represents an about $4.9 billion valuation.

Inari’s portfolio is complementary to Stryker’s Neurovascular business. It includes two novel mechanical thrombectomy solutions: the FlowTriever system for pulmonary embolism and the ClotTriever system for thrombectomy in the peripheral vessels. Inari’s portfolio also includes emerging therapies.

“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, Stryker’s chair and CEO. “We look forward to welcoming the talented Inari team to Stryker and working together to improve outcomes for patients worldwide.”

Upon the merger’s completion, Inari became a wholly-owned subsidiary of Stryker. Shares of Inari stopped trading before the open of the market on February 19, 205 and will be delisted from the Nasdaq Global Select Market.

In September 2024, the company acquired NICO Corp., a privately-held company that offers a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. NICO’s technologies integrate imaging and intervention to provide a safe, minimally disruptive approach to brain surgery.